Technology
Archived — This article has been archived. The information may be outdated.
Indian Scientists Develop Smart Cancer Drug RK-251
News On AIR··25 Aug
Researchers at IASST and IIT Guwahati have developed RK-251, an experimental prodrug designed to activate mainly inside cancer cells and release an anticancer compound called NBDHEX. In preclinical studies, it showed strong activity against aggressive triple-negative breast cancer cells while affecting healthy cells far less, with no toxicity signs in zebrafish tests. It has not been tested in humans.
Prism
What It Means For You
- If you or a family member has faced chemotherapy, this research points toward future treatments designed to spare healthy cells from damage.
- Cancer patients should know RK-251 is years away from clinical use, so current treatment options and doctor guidance remain unchanged for now.
- The work highlights Indian research institutions contributing to global cancer drug development, a field usually dominated by large international pharmaceutical companies.
What's Happening
- IASST's Dr Asis Bala and IIT Guwahati's Dr K P Bhabak developed RK-251, a prodrug that activates mainly inside cancer cells.
- In lab tests, RK-251 showed strong activity against triple-negative breast cancer cells while sparing healthy cells and showing no toxicity in zebrafish embryos.
- The research, published in the Journal of Medicinal Chemistry, has not yet advanced to human clinical trials.
How Far RK-251 Is From Patients
- RK-251 works as an activatable prodrug, staying inactive until high levels of reactive oxygen species inside cancer cells trigger it to release NBDHEX.
- Triple-negative breast cancer is considered especially aggressive and hard to treat because it lacks common hormone receptor targets used in other therapies.
- Developing a lab compound into an approved cancer drug typically takes years of further safety, dosage and clinical trial studies.
all-news
